PTO/SB/08A (10-01)
Approved for use through 10/31/2002.OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	10/077,555
Filing Date	February 15, 2002
First Named Inventor	Rong-Fu Wang
Art Unit	1645
Examiner Name	Not Yet Assigned
Attorney Docket Number	HO-P02373US1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
SR	BA	IB-98/46083-A1	10/22/1998	The Regents of the University of California		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

[1] Applicant's unique citation designation number (optional). [2] See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
SR	CA	Banchereau, Jacques, et al.; Dendritic cells and the control of immunity; Nature, Vol. 392, pp 245 - 252, March 19, 1998	
	CB	Bellone, Matteo, et al.; Relevance of the Tumor Antigen in the Validation of Three Vaccination Strategies for Melanoma; The Journal of Immunology, 2000, 165:2651 - 2656	
	CC	Cella, Marina, et al.; Inflammatory stimuli induce accumulation of MHC class II complexes on dentritic cells; Nature, Vol. 388, pp 782 - 787, August 21, 1997	
	CD	Celluzzi, Christina M., et al.; Peptide-pulsed Dendritic Cells induce Antigen-specific, CTL-mediated Protective Tumor Immunity; J. Exp. Med., Vol. 183, pp 283 - 287, January 1996	
	CE	Dallal, Ramsey M., et al.; The dendritic cell and human cancer vaccines; Current Opinion in Immunology 2000, 12:583 - 588	
	CF	Houghton, Alan N., et al.; Immunity against cancer: lessons learned from melanoma; Current Opinion in Immunology, 2001, 13:134 - 140	
	CG	Gilboa, Eli; The Makings of a Tumor Rejection Antigen; Immunity, Vol. 11, pp 263 - 270, September 1999	
	CH	Ludewig, Burkhard, et al.; Role of dendritic cells in the induction and maintenance of autoimmune diseases; Immunological Reviews 1999, Vol. 169:45 - 54	
	CI	Mehta-Damani, Anita, et al.; Generation of Antigen-specific CD8+ CTLs from Naive Precursors; The Journal of Immunology, 1994,153: 996 - 1003	
	CJ	Nestle, Frank O., et al.; Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells; Nature medicine, Vol. 4 (3), pp 328 - 332, March 1998	
	CK	Overwuk, Willem W., et al.; Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4+ T lymphocytes; Proc. Natl. Acad. Sci. USA (Immunology), Vol. 96, pp 2982 - 2987, March 1999	

Examiner Signature		Date Considered	10/18/05

PTO/SB/08A (10-01)
Approved for use through 10/31/2002.OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known	
Application Number	10/077,555
Filing Date	February 15, 2002
First Named Inventor	Rong-Fu Wang
Art Unit	1645
Examiner Name	Not Yet Assigned
Attorney Docket Number	HO-P02373US1

SR	CL	Paglia, Paola, et al.; Murine Dendritic Cells Loaded In Vitro with Soluble Protein Prime Cytotoxic T Lymphocytes against Tumor Antigen In Vivo; J. Exp. Med., Vol. 183, pp 317 - 322, January 1996	
	CM	Schreurs, Marco W. J., et al.; Dendritic Cells Break Tolerance and Induce Protective Ummunity against a Melanocyte Differentiation Antigen in an Autologous Melanoma Model; Cancer Research, Vol. 60, pp 6995 - 7001, December 15, 2000	
	CN	Schuler, G., et al.; Commentary - Dendritic Cells as Adjuvants for Immune-mediated Resistance to Tumors; J. Exp. Med., Vol. 186 (8), pp 1183 - 1187, October 20, 1997	
	CO	Thurner, Beatrice, et al.; Vaccination with Mage-3A1 Peptide-pulsed Mature, Monocyte-derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma; J. Exp. Med., Vol. 190 (11), pp 1669 - 1678, December 6, 1999	
	CP	Young, James W., et al.; Dendritic Cells as Adjuvants for Class I Major Histocompatibility Complex-restricted Antitumor Immunity; J. Exp. Med., Vol. 183, pp 7 - 11, January 1996	
	CQ	Wang, Rong-Fu, et al.; Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells; Nature Biotechnology, Vol. 20, pp 149 - 154, February 2002	
	CR	Wang, Rong-Fu, et al.; Human tumor antigens for cancer vaccine development; Immunological Reviews, Vol. 170:85 – 100, 1999	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	10/18/05